NTAP
64
2
CVS
48
3
ORLY
53
-3
HSY
34
3
EFX
32
2
STI
47
-12
ZBH
60
-2
NWSA
62
2
PBI
60
-5
CL
56
5
NRG
49
-3
JNPR
46
3
UNH
61
6
ADP
64
2
HRL
39
15
RRC
63
3
PNW
66
3
FDX
36
-4
AZO
46
-3
CINF
47
2
NTAP
64
2
CVS
48
3
ORLY
53
-3
HSY
34
3
EFX
32
2
STI
47
-12
ZBH
60
-2
NWSA
62
2
PBI
60
-5
CL
56
5
NRG
49
-3
JNPR
46
3
UNH
61
6
ADP
64
2
HRL
39
15
RRC
63
3
PNW
66
3
FDX
36
-4
AZO
46
-3
CINF
47
2
Financhill
Back

Bristol-Myers Squibb 10K Form

Buy
53

BMY
Bristol-Myers Squibb

Last Price:
57.89
Seasonality Move:
2.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BMY News And Ratings

See the #1 stock for the next 7 days that we like better than BMY

BMY Financial Statistics

Sales & Book Value

Annual Sales: $45.01B
Cash Flow: $5.27B
Price / Cash Flow: 8.35
Annual Sales: $8.45
Price / Book: 6.72

Profitability

EPS (TTM): -3.59000
Net Income (TTM): $-7.26B
Gross Margin: $34.31B
Return on Equity: -33.18%
Return on Assets: -7.66%

Bristol-Myers Squibb Earnings Forecast

Key Bristol-Myers Squibb Financial Ratios

  • The Gross Profit Margin over the past 37 years for BMY is 76.24%.
  • The Selling, General & Administrative Expenses for BMY have been equal to 17.27% of Gross Profit Margin.
  • The Research & Development expenses have been 20.66% of Revenue.
  • The Interest Expense is 14.53% of Operating Income.
  • The Net Earning history of BMY is 17.83% of Total Revenues.
  • Per Share Earnings over the last 37 years have been positive in 19 years.

Bristol-Myers Squibb Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: BMY
CUSIP: 110122
Website: bms.com

Debt

Debt-to-Equity Ratio: 2.9
Current Ratio: 1.24
Quick Ratio: 1.02

Price-to-Earnings

Trailing P/E Ratio: 14.72
Forward P/E Ratio: 8.05

BMY Technical Analysis vs Fundamental Analysis

Buy
53
Bristol-Myers Squibb (BMY) is a Buy

Is Bristol-Myers Squibb a Buy or a Sell?